End-to-End Manufacturing at a Single Site and High-throughput Vector Suite Design Will Bolster Batch Production Up to Five Times

King of Prussia, PA — December 08, 2022 —The Center for Breakthrough Medicines (CBM), a contract development, manufacturing, and testing organization (CDMO) has launched Genesis Vector Manufacturing SolutionsTM to help innovator companies reimagine vector manufacturing by simplifying the value chain and accelerate their path to clinic and commercial launch.

CBM’s Genesis Vector Manufacturing SolutionsTM is an end-to-end offering that includes plasmid manufacturing, first-time right process development and high-throughput GMP vector manufacturing suites to accelerate development and manufacturing timelines. Integrated testing & analytics, supply chain, and regulatory services co-located with manufacturing at a single site drastically simplifies the vector value chain. CBM’s new, purpose-built facility is engineered and outfitted to support a wide variety of vectors, including viral-based products (such as those used for gene-modified cell therapies in CBM’s previously announced expansion) as well as other novel biologically derived delivery vectors compliant with the most robust segregation controls.

“This past year has been a catalyst moment for gene therapies with approvals and authorizations doubling the number of treatments available, accelerating the need for high throughput manufacturing of diverse vectors used to deliver lifesaving therapies,” said Audrey Greenberg, CBM’s Co-founder and Chief Business Officer. “We are thrilled to complete phase one of our 200,000 sq. ft high-throughput GMP vector production facility which sits alongside in-house plasmid production, testing, and analytics. Our investment in 700,000 sq. ft of capacity and expertise will allow innovator companies to optimize their working capital and focus on driving the science forward.”

Read the full article at: breakthroughmedicines.com